Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights

Area of Science:

• Oncology
• Melanoma Research
• Molecular Targeted Therapy

Background:

• Advanced melanoma treatment has been revolutionized by BRAF/MEK inhibitors for BRAFV600 mutations.
• BRAFV600 wild-type melanoma presents unique therapeutic challenges.
• Understanding diverse mutation profiles is crucial for effective treatment strategies.

Purpose of the Study:

• To review current data on small-molecule targeted therapies for advanced BRAFV600 wild-type melanoma.
• To explore future therapeutic strategies beyond BRAFV600 mutations.
• To assess the efficacy of novel combinations in different melanoma subtypes.

Main Methods:

• Literature review of recent clinical trials and preclinical studies.
• Analysis of data on MEK-inhibitors, RAF dimer inhibitors, and CDK4/6-inhibitors.
• Focus on BRAFV600 wild-type melanoma and other relevant mutations (NRAS, NF1, cKIT).

Main Results:

• MEK-inhibitors show limited activity in NRASQ61 mutant melanoma, but combinations with RAF dimer or CDK4/6 inhibitors are promising.
• MEK-inhibition +/- BRAF-inhibition appears effective in non-V600 BRAF mutant melanoma, with RAF dimer inhibitors under investigation.
• No molecular-targeted therapies have improved survival in BRAFV600 wild-type melanoma yet; combinations are under investigation.
• Imatinib/nilotinib show efficacy in cKIT mutant melanoma.
• Cobimetinib plus atezolizumab did not outperform pembrolizumab in BRAF/NRAS/NF1 wild-type melanoma.

Conclusions:

• Currently, no molecular-targeted therapies significantly improve survival in advanced BRAFV600 wild-type melanoma.
• Combinatorial approaches using MEK-inhibitors, RAF dimer inhibitors, and CDK4/6-inhibitors show promise.
• Further research and prospective trials are needed to validate these strategies.